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Abstract
The right to health as a basic human right- and access to medicine as a part of it- have been a matter of attention
for several decades. Also the responsibilities of different parties- particularly pharmaceutical companies- in
realization of this right has been emphasized by World Health Organization. This is while many companies find no
incentive for research and development of medicines related to rare diseases. Also some legal structures such as
“patent agreements” clearly cause huge difficulties for access to medicine in many countries. High prices of brand
medicine and no legal production of generics can increase the catastrophic costs- as well as morbidity-mortality of
medication in lower income countries. Here we evidently review the current challenges in access to medicine and
critically assess its legal roots. How societies/governors can make the pharmaceutical companies responsible is also
discussed to have a look on possible future and actions that policy makers- in local or global level- can take.
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Background
Responsibilities of pharmaceutical companies with
regard to human rights have been matter of debates for
many years. In August 2008, the Secretary-General of
United Nations published a report which mentioned that
over 2 billion people all over the world do not have suffi-
cient access to essential medicine [1]. The message was
clear, two billion people (about one third of the world
population at the time) were in danger of death or major
harm to their health as a result of the lack of access to
essential medicines, either because of not enough atten-
tion from pharmaceutical companies, or because the
state parties could not fulfill their obligation in regards
to essential medicines.
Now after a couple of years it might be still a question
that, what the responsibilities of different parties (such
as pharmaceutical companies, governments, NGOs,
world organizations etc.) are for solving this problem,
and how we can assure that the realization of access to
essential medicines takes place? This paper will discuss
these questions briefly from a human rights perspec-
tive, and we will try to find and summarize some legal
solutions for controversies and complexities in this
field.
What are the roots of the problem?
Huge part of barriers in access to medicine returns to
patent law and its consequences. Although patent law
generally has been used for centuries [2], the manifest-
ation of TRIPS agreement in 1994 turned it to a new
form of challenge. This agreement force the World
Trade Organization (WTO) members to take action for
protecting intellectual property rights, which entails that
any patented product should be produced, imported,
sold or used under permission of the patent owner [3].
This includes medicine, thus the production of each
medicine is initiated with a period of monopoly in the
market with the highest possible price. In this period
there will be no low price generic drugs in the market
after signing the agreement by one state (for those drugs
which are still under patent), and hence, patients should
provide the expensive branded medicine either out of
pocket or by using their insurance.
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The problem will rise up when it comes to a develop-
ing country where population not only have lower eco-
nomic status, but also lower health status and higher
needs to medicine. According to WHO, life expectancy
in developed countries was 1.7 fold higher than develop-
ing countries in 2002, showing a 32-years gap in life ex-
pectancy between these societies [4]. Also, data shows
that infectious diseases such as TB have a negative rela-
tionship with GDP per capita of the country [5] (also see
Fig 1). These health measures make it obvious that in
developing countries there is a higher need to medical
technologies which many of them are under patent. At
the same time, health insurance coverage is usually poor
in these countries and patients often have to pay for the
branded medicine out of their own pockets. Evidence
shows that the lower the national income is, the higher
the out of pocket share of health spending will be [6].
With higher needs and lower economic ability, providing
branded medicine will result in a large load of expend-
iture for states, catastrophic expenditures for patients [7]
and increase of mortality and/or morbidity because of
low access to medicine (see Fig 2).
Moreover, if any TRIPS member produce or provide
an under patent product, the company can sue the
member state and ask for a fine compensating the mar-
ket loss. This was the case for South Africa in late 90s,
when giant pharmaceutical companies such as GlaxoS-
mithKline filed a lawsuit to the Pretoria High Court
against the South African government because of im-
portation of generic anti-retroviral medicine- for treating
HIV/AIDS endemic situation [8]. The Pharmaceutical
Association was using this law to save their presence in
Fig. 1 Health and wealth relationship: a Increase in life expectancy
by wealth; wealthier countries (higher GDP per capita) having higher
life expectancy, showing a health inequality in the world;
b higher prevalence of TB- as a chronic communicable disease- in
low income countries. Free material from www.gapminder.org
Fig. 2 Lower health insurance services in lower income countries:
a decrease in out-of-pocket (OOP) share of health expenditures by
increase in GDP per capita (Data from World Bank [21, 22]); b increase in
catastrophic expenditures by increase of OOP share; plot from Van
Doorslaer et al. [7] (with copy right permission from John Wiley and
Sons). These figures depict that lower income can result in lower health
insurance services (higher out-of-pocket expenditure for health) and
hence higher incidence of catastrophic expenditures consequently, which
can cause an inequality in health and social gaps between populations
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the pharmaceutical market of South Africa. However,
there were millions of people suffering from HIV/AIDS
while could not afford the original brand medicine and
the South African state was trying to find a way to guar-
antee their health. After three years of clashes, the court
overruled the patent law in the case and recognized the
right to health as a basic human right for the South
African patients. Consequently big pharma companies
withdrew the lawsuit and started negotiations for drop-
ping the price of original brand to come into the South
Africa market [9].
Although this was a happy-ending experience, no
country can be sure that the court will give the right to
the member state again and hence, in many cases the
government prefer to import the branded medicine from
the beginning, even if it is not affordable for a part of
population.
The TRIPS agreement is not the end of story. Less
than a decade after the first TRIPS agreement, United
States started to make bilateral trade agreements with
other TRIPS members to expand and deepen the TRIPS
agreement. These agreements (generally known as TRIPS-
plus) decrease the flexibilities which were anticipated for
some exceptional situations- particularly for developing
countries- and increase the duration of patents in some
cases. Until now, there are 20 countries that accepted such
an agreement with US [10], which surprisingly 80 % of
them are developing countries. If we consider the eco-
nomic power of United States and its role in pharmaceut-
ical industry, then it is not hard to guess about the effect
of these agreements on the access to medicine in the sub-
jected developing countries.
Besides the patent law and TRIPS-plus agreements,
there is always a bias towards maintenance medicine-
the controlling medicine for chronic conditions.
Pharmaceutical companies have a substantial desire in
developing drugs which are focused on disease areas
within the developed world, such as chronic diseases
and cancer treatments, not only because of high preva-
lence, but also because these drugs are often used in
long term, which means a long term costumer for the
company, particularly if one can take the advantage of
patent. As an instance, a new anti-hypertensive medicine
not only has more costumers, also most of the cos-
tumers have to use the medicine until the end of their
lives, let’s say 10–15 years in average. On the other side,
giant pharmaceutical companies are less interested in
modern anti-parasites, antibiotics and other medicines
related to acute conditions, while these medicines are
more needed in developing countries and this bias cause
a lower access to medicine- and a lower health in result-
in these low income areas.
The mentioned bias also can be seen against “rare dis-
eases” (i.e., diseases with prevalence less than 1/2000),
even if they might be chronic. This inattentiveness to
some specific diseases forms when the disease is rare or
restricted to some particular areas and population, hence
pharmaceutical companies find no incentive to invest on
research and development of new medicine specified for
a limited population, specifically when there is a large
possibility that the state does not have the ability to pay
for the medicine and the company should provide it
underprice.
To see it evidently, from over 1500 drugs which have
been approved during 1975–2004, only about 1 % of
them were related to the diseases which are known as
neglected [11], while over 10 % of global burden of dis-
ease is caused by these diseases [12]. This is also
reflected in 10/90 phenomena: only 10 % of R&D expen-
ditures is related to problems of 90 % of world popula-
tion [13]. These facts clearly show an insufficient
attention from pharmaceutical companies to this field of
health needs. According to WHO, already over one bil-
lion people are affected by neglected tropical diseases
[14], which may considerably decrease both the life ex-
pectancy and quality of life. By considering the higher
rate of these diseases in low income countries, it is to
say that this situation can cause a huge discrimination
between high and low income societies, not only in
terms of health, but also economically as a consequence
of low health level.
All these modern structures, from patents and TRIPS-
plus agreements to bias in pharma industry, cause a de-
crease or imbalance in access to medicine, and hence an
inequity in health between and within the communities,
which can be considered as a breach of human rights as
will be explained further.
Human rights and the role of pharmaceutical
industry
Previously in 2000, United Nations established eight
goals as Millennium Development Goals and 190
countries agreed to help to achieve these goals by
2015. At least three of these goals- reduction of child
mortality, improve of maternal health, and combating
HIV/AIDS, malaria, and other diseases- are extremely
dependent on accessible and affordable medicine. Even
the role of pharmaceuticals is clearly mentioned in the
millennium declaration: “Develop a global partnership for
development- In co-operation with pharmaceutical com-
panies, provide access to affordable, essential drugs in de-
veloping countries; proportion of population with access
to affordable essential drugs on a sustainable basis” [15].
The strong influence of pharmaceutical companies on
accessibility and affordability of medicine is clear. But
should they be responsible for the realization of access
to medicines?
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As first point, health is considered as a basic human
right, as it is stated in article 12 of International Coven-
ant on Economic, Social and Cultural Rights, “the States
Parties to the present Covenant recognize the right of
everyone to the enjoyment of the highest attainable
standard of physical and mental health” [16]. And we
should beware that, according to UN, the responsibilities
which are stated in human rights declaration are not
solely an obligation for the member states, but the pri-
vate sector is equally subjected to human rights respon-
sibilities [17].
Moreover, investing on modern chronic disease and
neglecting other diseases such as tropical infections (e.g.,
leishmaniasis), is clearly inequitable and can increase the
rich-poor gap. This socioeconomic gap is an issue to be
noticed and should be prevented, which is not possible
without serious contribution of pharmaceutical compan-
ies. One may mention the super costly research and de-
velopment in the field of rare disease, but in response
we should look at the both sides; costs and revenues. Al-
though it is said that pharmaceutical companies spend
around $60 billion for research and development, it
should be also mentioned that the annual revenue of
these companies exceeds 300 billion [18], which easily
covers the cost of R&D. With such an income, it is just
an insincere gesture to talk about the R&D costs as a
reason of keeping high price for the products.
But even with accepting all these responsibilities, what
or who can make the pharmaceutical companies respon-
sible and to make commitment to human rights?
Making big pharma responsible: legal and social
capacities
Since start of these debates, there have been several sug-
gestions for achieving accountability of pharmaceutical
companies. These suggestions are mainly classified in
two groups of top-down (interventions from govern-
ments and international regulators) and bottom-up
(pressure from NGOs and social organizations).
Top-down
As mentioned before, highest attainable standard of
health, which includes access to essential medicines, is
one of the human rights that states should ensure. Le-
gally, governments that have signed the international
treaties of human rights are expected to prevent viola-
tion of human rights even. Legislative bodies can play a
major role in steering the activities of big pharma and
prevent such violations. At first glance, governments
might not be able to restrict the pricing directly and/or
their trade activities since it is against WTO regulations
and TRIPS agreement. Moreover, it is too complicated
to define a definite crime in this field, in a way that no
one can escape from the law, and at the same time not
making barriers for the enjoyment of the right of free
trading. But in the wide field of pharmaceutical trading,
there are still other ways to make appropriate restric-
tions, directly and indirectly.
Currently the most applicable way is antitrust or com-
petition law, which protect the presence of competition
in the market and fight against corruptions. Many patent
owner may find it tempting to have the monopoly of
market and be the only brand even after patent expir-
ation. Hence these companies may form secret agree-
ments with generic producers to postpone the entrance
of low price generic medicine into the market. Antitrust
law bans any act that big pharma companies can take to
stop other companies from producing the generic prod-
ucts after patent expiration. By saving the competition,
this law guarantee the decrease of price in a reasonable
time and hence, increase of affordability of the medicine.
This way can be very effective for medicines which their
patent is already expired or is going to expire in near
future.
Another important step to solve the patent problem
was taken by WTO itself with Doha Declaration in
2001. After all debates and discussions on how TRIPS
agreement can harm human population health, finally
member states decided to make an escape way for emer-
gency situations by waiving the strict TRIPS agreement:
“the gravity of the public health problems afflicting many
developing and least-developed countries, especially
those resulting from HIV/AIDS, tuberculosis, malaria
and other epidemic… the TRIPS Agreement does not
and should not prevent Members from taking measures
to protect public health” [19]. It also clearly mentions
the assuming public health problems in paragraph 5 (c):
“Each Member has the right to determine what consti-
tutes a national emergency or other circumstances of ex-
treme urgency, it being understood that public health
crises, including those relating to HIV/AIDS, tubercu-
losis, malaria and other epidemics, can represent a na-
tional emergency or other circumstances of extreme
urgency” [19]. Unfortunately these efforts were not
much of success and major countries such as United
States, Japan, Switzerland and Australia did not make
any domestic legislative implementation for TRIPS Wai-
ver while over 100 countries had accepted to do so [20].
There are also indirect ways for states to control big
pharma and steer them to accept more responsibility for
human rights. As an instance, it is suggested to mandate
a certain level of transparency for pricing and its details,
so that everyone will know if the price is logical in com-
parison to the costs. Although it seems to be an applic-
able effective approach, it has its own shortages. First of
all, it can harm the market and competition since it re-
veals companies secrets and can be abused by other
companies. Also, it can be misinterpreted by people and
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the media, since nobody knows which margin of interest
is fair enough for the company, particularly by consider-
ing next projects and future investment programs. Simi-
lar suggestion may be made for disclosure of exact
amount of donations and also the tax benefit resulted
from this donation. In this way the company clearly
shows their social contribution and the amount of effort
they make to increase accessibility. This method might
be more applicable; it is less problematic and makes
more sense to public opinion.
All in all, while these top-down approaches might be
helpful, the legal complexities have resulted in a long
lasting pause in the current situation.
Bottom-up
The other group of actions are known as bottom-up,
which means actions that are taken by society (as indi-
viduals or NGOs) to control and/or affect pharmaceut-
ical companies.
The best known- and probably most effective- project in
this area is “Access to Medicine Index”. This index was in-
novated and introduced in 2008 by Bill & Melinda Gates
Foundation and measures the amount of activities of big-
gest pharmaceutical manufacturers in means of increasing
access to essential medicine all around the world [21]. In
this index 7 fields of activities have been considered with
different weights: “Pricing, manufacturing and distribut-
ing” with 25 %, “research and development” with 20 %,
“Patent and licencing” with 15 % and “general access to
medicine management”, “market influence”, “capacity
building”, “product donations” each with 10 % share of
scores. Each of these fields are assessed based on 4 main
criteria: commitment, transparency, performance and
innovation. As an instance, Gilead Science Inc. had the
highest score in the two fields of “pricing” and “patents” in
recent years. This is probably because of increasing access
to its new anti-viral medicine sofosbovir (Sovaldi) which
has been provided 99 % off price for developing countries
[22]. Although this medicine is provided with about $1200
per pill in US [23], Gilead allowed generic licencing in de-
veloping countries so that the medicine can be accessible
in very low price and save lives of millions of people with
hepatitis C, as well as its benefit from the market. Other
examples also can be seen in the index report which
clearly shows the improvements and lacks of the compan-
ies’ policies.
At first glance it might be a simple index like thou-
sands of other scientific measures. However, looking
closer at the index one can notice that it is effectively
encouraging big pharma to increase the access to their
products in their own way and without any legislative
obligation. Hogerzeil et al. showed that average score of
these big pharmaceutical companies increased since
2010 to 2012 and we can be hopeful about continue of
this increasing trend [24]. The reasons that may explain
this positive effect, first is the attempts of companies to
improve their image in the public opinion, which might
be a promotion for their products and attract direct cos-
tumers. And second, the effect of improving public
image on share values and convincing more shareholders
to invest on the company. However, this encouraging ef-
fect is still a theory and not proven yet, particularly in
long term. By looking at the index for 2014 we can see a
decreasing trend for most of the companies since 2012.
It seems that even if it is effective, it cannot be a guaran-
tee for improvement of access to medicine overtime.
In addition, this measure potentially can be used as a
precise definition for crimes, and to make legal actions
for controlling pharmaceutical companies. As a broad
example, we can imagine a law that mandates having a
minimum score of Access to Medicine Index, and com-
panies which get lower score will be penalized. In this
way Access to Medicine Score is not just an honor
which can be neglected by some companies or in some
situations, but pharmaceutical companies have to try for
it. This can be an answer to our question about “defin-
ition of crime” which mentioned before.
Other bottom-up approaches are also using the same
trick. “Naming and shaming” by NGOs and world orga-
nizations can be an effective way, using “punishment” in-
stead of encouragement. In this way, campaigns and
movements can be used to openly blame the companies
which explicitly avoid helping for improving access to
medicine, so that the public opinion and media stream
may make a pressure to these companies for accepting
their responsibilities.
Current legal challenges and future efforts to
make
Although it is 2015 and at least main parts of this prob-
lem were supposed to be solved by now, there is still a
big capacity to change the situation. Having only some
ethical guidelines and declarations after all these years
shows a hanging situation and can be a clue that we
need a break in the current framework to make a new
paradigm. This new paradigm might be a different point
of view in assumptions and philosophical theories that
are being used as basis of world legal systems.
As an example, currently human rights are still inter-
preted from its conventional point of view. Human
rights were initially established to protect mainly ‘hu-
man’ from the ‘state’, and majority of laws gave the ori-
ginality to individuals and their freedom. But during
these decades there has been a shift in the society to
where the state does not have its previous major role in
many areas, and non-state actors like pharmaceutical
companies have started to play a more important role,
which means there is a need to protect individuals from
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other ‘individuals’ who are free to make inequitable con-
ditions- such as inequity in medicine production or pri-
cing. Despite all these shortages and complications,
there are no legal obligations for the private sector to
obey human rights, i.e., the human rights are not ‘legally
binding’ directly to pharmaceutical companies. The new
legal framework is to find new ways to guarantee the
proper contribution of these companies in human rights.
As a legal suggestion, an international effort can be
made to oblige big pharma to sign the human rights treat-
ies. By this mean, the enquiry of pharmaceutical compan-
ies and the assessment of their practice will be legally
possible by international organizations. The first question
will be if pharmaceutical companies are legally allowed to
sign the treaty. One may refer to International Covenant
on Economic Social and Cultural Rights (ICESR) article 8,
where trade unions are known as legal persons in this law
to have the right, and by definition, we may conclude that
legal persons may be addressed to legal obligations as well
as legal rights. Following this interpretation, even if
pharmaceutical companies are not able to sign the cove-
nants themselves, their professional union or association-
either international or domestic- can be obliged to sign
treaties and accept the commitments to provide affordable
and accessible medicine for all disease categories.
Moreover, one of the major problems with current
paradigm is the lack of incentives for states to make
these new regulations, either because they do not see
the access to medicine as their own problem, or because
they are taking the advantage of the taxes coming from
these pharmaceuticals, and restricting them is equal to
losing part of this huge tax. Hence, governments might
not be much interested in these types of regulations
even though it is against their commitments to human
rights covenant. Drawing on this point of view, world
authorities may be able to establish new laws not only
for controlling the trade and accountability of manufac-
turers, but also for more contribution of states. If mem-
ber states be known as main responsible (instead of
pharmaceutical companies) they will have enough incen-
tives to find new ways to make pharmaceutical compan-
ies to co-operate or to compensate their share of
contribution.
Legitimacy of TRIPS-plus agreements also can be criti-
cized as a barrier for realization of human rights. Accord-
ing to Article 41 the Vienna Convention on the Law of
Treaties, although having unilateral or multilateral agree-
ments or modifications within members is allowed, it
should be only in a way which does not affect the enjoy-
ment of other members of treaty from the enjoyment of
their rights as defined in the treaty. In our case of pharma-
ceutical companies, when United States- as one of the
major owners of pharmaceutical companies- makes
TRIPS-plus agreements and expand the patent duration
in several countries- while some of them own big generic
producers, and many of them are big generic consumers-
it can be against the enjoyment of other member states,
either those which want to buy generic products, or those
that want to export generic products to subjected develop-
ing countries. Hence these agreements are not just
restricting for the countries signing them, but also for
many other TRIPS members.
In addition to these flaws of TRIPS-plus agreement, it
can be also criticized in a human rights point of view
that suggestion of such an agreement to developing
countries- while it is predictable that the country will
have big problems in purchase of medicine- is against
human rights.
To sum up, the most important actions to take are
making pharmaceutical unions or associations respon-
sible by signing human right treaties, increasing the re-
sponsibility and contribution of member states and
making TRIPS-plus agreements less effective.
Conclusion
Health is a basic human right and access to medicine is
a basic tool to ensure health. This right and its tools are
facing major issues in the world. Pharmaceutical com-
panies play a substantial role in increasing the access to
medicines in order to guarantee health.
Till now and despite all shortages and difficulties, re-
markable efforts have been made. Major pharmaceutical
companies are helping billions of dollars by donating
medicine to poor population or patients with neglected
disease. WHO and human rights committee of United
Nations also make several heads-up every year and seek
new ways to improve the situation of access to medicine
in co-operation with NGOs and governmental organiza-
tions. Also states have tried to create a better circum-
stance for increasing the availability and affordability of
medicine. However, there is still a substantial need for
improvements, as well as the notable potential for mak-
ing changes.
More realistic accountability of different parties- in-
cluding both states and big pharmaceutical companies-
is the main necessity in this way. Without this account-
ability, there will be no real and long term change in the
situation and every step would work as a temporary
painkiller, but not as a cure.
Also it should be considered that this accountability
cannot be realized automatically or through ethical advice,
but needs serious legal acts in terms of defining crimes,
binding state and non-state parties to increase their co-
operation and to make a safe way for access to generic
medicine in developing countries by restricting TRIPS and
TRIPS-plus agreements. With all these efforts we can be
hopeful that delayed goals for increasing health and de-
creasing inequity will be achieved.
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